Drugs / HD quadrivalent influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06134804 | Oct 2023 → Feb 2024 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD quadrivalent influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134804 ↗ |
| Modality | Vaccine | “HD quadrivalent influenza vaccine” NCT06134804 ↗ |
| Route | Intramuscular | “HD quadrivalent influenza vaccine will be administered as IM injection.” NCT06134804 ↗ |